Endocrine function after transplantation for sickle cell disease
| Patient No. . | Indication for BMT . | Sex . | Age at BMT (y) . | Age at Follow-Up (y) . | Baseline Studies* . | Current Studies* . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LH (mIU/mL) . | FSH (mIU/mL) . | Estr (pg/mL) . | Testo (ng/dL) . | LH (mIU/mL) . | FSH (mIU/mL) . | Estr (pg/mL) . | Testo (ng/dL) . | |||||
| 1 | Stroke | F | 10.5 | 17.4 | 63 | — | 29† | |||||
| 2 | Stroke | M | 10.6 | 16.2 | <0.2 | <0.5 | 3.3 | 10.7 | 4.1 | — | ||
| 3 | Stroke | F | 10.2 | 15.8 | 9.1 | 2.4 | — | |||||
| 5 | ACS, TIAs | M | 11.3 | 16.2 | — | — | — | |||||
| 6 | ACS/abnl MRI | M | 12.2 | 17.0 | 10 | 7.3 | ||||||
| 8 | ACS | F | 14.0 | 18.6 | 1.1 | 1.5 | <20 | 41.4 | 15.8 | <20 | ||
| 10 | VOC/abnl TCD | F | 8.36 | 14.1 | 25 | 4.38 | <20 | |||||
| 12 | ACS | F | 13.7 | 18.4 | 7.2 | 3.1 | 80.9 | — | 9.2 | 73.7 | ||
| 14 | Stroke | M | 12.3 | 16.6 | 1.5 | 0.5 | 18 | 1.9 | 0.5 | 8 | ||
| 15 | Stroke | M | 13.3 | 17.7 | — | — | — | |||||
| 16 | VOC | M | 10.1 | 14.5 | 1.2 | <0.5 | — | |||||
| 20 | Stroke | F | 12.2 | 15.6 | 38.1 | 13.3 | 24 | |||||
| 21 | VOC | M | 13.9 | 19.2 | — | — | — | |||||
| 26 | ACS, abnl MRI | F | 12.4 | 14.8 | 4 | <0.5 | — | 128 | 51.6 | — | ||
| Patient No. . | Indication for BMT . | Sex . | Age at BMT (y) . | Age at Follow-Up (y) . | Baseline Studies* . | Current Studies* . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LH (mIU/mL) . | FSH (mIU/mL) . | Estr (pg/mL) . | Testo (ng/dL) . | LH (mIU/mL) . | FSH (mIU/mL) . | Estr (pg/mL) . | Testo (ng/dL) . | |||||
| 1 | Stroke | F | 10.5 | 17.4 | 63 | — | 29† | |||||
| 2 | Stroke | M | 10.6 | 16.2 | <0.2 | <0.5 | 3.3 | 10.7 | 4.1 | — | ||
| 3 | Stroke | F | 10.2 | 15.8 | 9.1 | 2.4 | — | |||||
| 5 | ACS, TIAs | M | 11.3 | 16.2 | — | — | — | |||||
| 6 | ACS/abnl MRI | M | 12.2 | 17.0 | 10 | 7.3 | ||||||
| 8 | ACS | F | 14.0 | 18.6 | 1.1 | 1.5 | <20 | 41.4 | 15.8 | <20 | ||
| 10 | VOC/abnl TCD | F | 8.36 | 14.1 | 25 | 4.38 | <20 | |||||
| 12 | ACS | F | 13.7 | 18.4 | 7.2 | 3.1 | 80.9 | — | 9.2 | 73.7 | ||
| 14 | Stroke | M | 12.3 | 16.6 | 1.5 | 0.5 | 18 | 1.9 | 0.5 | 8 | ||
| 15 | Stroke | M | 13.3 | 17.7 | — | — | — | |||||
| 16 | VOC | M | 10.1 | 14.5 | 1.2 | <0.5 | — | |||||
| 20 | Stroke | F | 12.2 | 15.6 | 38.1 | 13.3 | 24 | |||||
| 21 | VOC | M | 13.9 | 19.2 | — | — | — | |||||
| 26 | ACS, abnl MRI | F | 12.4 | 14.8 | 4 | <0.5 | — | 128 | 51.6 | — | ||
Abnl = abnormal; ACS = acute chest syndrome; BMT = bone marrow transplantation; estr = estradiol; FSH = follicle stimulating hormone; LH = luteinizing hormone; MRI = magnetic resonance imaging; TCD = transcranial Doppler; Testo = total testosterone; TIA = transient ischemic attack; VOC = vaso-occlusive crisis.
Normal values: FSH (adult males, 1.0-10.3; adult females, 1.9-10.2); LH (adult males, 1.0-10.0; adult females, 2.1-15.3); total testosterone, 275-875 (adult males); estradiol, 15-260 (luteal phase in adult females), prepubertal females, <25.40 41
Receiving hormonal replacement therapy.